Literature DB >> 1539847

Comparison of ketorolac and morphine as adjuvants during pediatric surgery.

M F Watcha1, M B Jones, R G Lagueruela, C Schweiger, P F White.   

Abstract

The intraoperative use of opioid analgesics decreases the volatile anesthetic requirement and provides for pain relief in the early postoperative period. In a randomized double-blind, placebo-controlled study involving 95 ASA physical status 1 or 2 children (ages 5-15 yr) undergoing general anesthesia for elective operations, we compared postoperative analgesia following the intraoperative intravenous (iv) administration of ketorolac, a nonsteroidal antiinflammatory drug or morphine, an opioid analgesic. After induction of general anesthesia and before the start of the surgical procedure, children received equal volumes of saline, morphine (0.1 mg.kg-1, iv) or ketorolac (0.9 mg.kg-1, iv). Postoperative pain was evaluated by the child using a 10-cm linear visual analog scale (VAS) and by a blinded observer using both a VAS and an objective pain scale (OPS) in the postanesthesia care unit (PACU). There were no statistically significant differences in the VAS and OPS scores in the PACU or in the postoperative analgesic requirements in children receiving morphine or ketorolac. The placebo group had a significantly higher VAS and OPS score and required earlier and more frequent analgesic therapy in the PACU compared to the two analgesic groups. Patients receiving ketorolac had less postoperative emesis than those receiving morphine. We conclude that ketorolac (0.9 mg.kg-1) is an effective alternative to morphine (0.1 mg.kg-1) as an iv adjuvant during general anesthesia, and in the dose used in this study, is associated with less postoperative nausea and vomiting in children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539847     DOI: 10.1097/00000542-199203000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  22 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Post-operative pain management.

Authors:  R A Berkowitz; T B McDonald
Journal:  Indian J Pediatr       Date:  1997 May-Jun       Impact factor: 1.967

Review 4.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

Review 5.  Minimising the adverse effects of ketorolac.

Authors:  D I Reinhart
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

6.  Preoperative ketorolac increases bleeding after tonsillectomy in children.

Authors:  W M Splinter; E J Rhine; D W Roberts; C W Reid; H B MacNeill
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

7.  Comparative evaluation of pre-emptive analgesic efficacy of intramuscular ketorolac versus tramadol following third molar surgery.

Authors:  Ashwin V Shah; K V Arun Kumar; Kirthi Kumar Rai; B P Rajesh Kumar
Journal:  J Maxillofac Oral Surg       Date:  2012-09-23

8.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

9.  Comparative effects of three doses of intravenous ketorolac or morphine on emesis and analgesia for restorative dental surgery in children.

Authors:  J P Purday; C C Reichert; P M Merrick
Journal:  Can J Anaesth       Date:  1996-03       Impact factor: 5.063

10.  Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Authors:  Laurel M Adams; Brendan Johnson; Ke Zhang; Lin Yue; Lyndon C Kirby; Peter Lebowitz; Randall Stoltz
Journal:  Support Care Cancer       Date:  2009-02-10       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.